enGene (NASDAQ:ENGN) Downgraded to "Neutral" Rating by UBS Group

UBS Group downgraded shares of enGene (NASDAQ:ENGN - Free Report) from a buy rating to a neutral rating in a research note released on Friday, Marketbeat.com reports. They currently have $7.00 price target on the stock, down from their previous price target of $34.00.

Other equities research analysts have also issued research reports about the stock. Citizens Jmp raised shares of enGene to a "strong-buy" rating in a report on Monday, November 18th. Raymond James began coverage on shares of enGene in a report on Wednesday, November 27th. They set an "outperform" rating and a $23.00 target price for the company. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 target price on shares of enGene in a report on Monday, December 23rd. Finally, HC Wainwright initiated coverage on shares of enGene in a report on Monday, December 23rd. They issued a "buy" rating and a $25.00 price objective for the company. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, enGene currently has a consensus rating of "Buy" and a consensus target price of $26.40.

enGene Price Performance

NASDAQ ENGN traded up $0.13 on Friday, hitting $6.03. The company had a trading volume of 78,017 shares, compared to its average volume of 145,652. The company has a market capitalization of $266.43 million, a PE ratio of -10.39 and a beta of -0.65. The company's fifty day moving average price is $6.83 and its 200-day moving average price is $7.23. The company has a debt-to-equity ratio of 0.08, a current ratio of 16.87 and a quick ratio of 16.87. enGene has a 12-month low of $4.42 and a 12-month high of $18.40.

enGene (NASDAQ:ENGN - Get Free Report) last released its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.06. As a group, analysts predict that enGene will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of ENGN. Deep Track Capital LP lifted its position in enGene by 74.8% in the fourth quarter. Deep Track Capital LP now owns 4,557,575 shares of the company's stock valued at $30,308,000 after buying an additional 1,949,942 shares during the last quarter. VR Adviser LLC lifted its position in enGene by 41.5% in the fourth quarter. VR Adviser LLC now owns 5,046,414 shares of the company's stock valued at $33,559,000 after buying an additional 1,480,573 shares during the last quarter. Fcpm Iii Services B.V. lifted its position in enGene by 11.0% in the fourth quarter. Fcpm Iii Services B.V. now owns 9,632,561 shares of the company's stock valued at $64,057,000 after buying an additional 954,610 shares during the last quarter. Orbimed Advisors LLC acquired a new position in enGene in the fourth quarter valued at about $6,120,000. Finally, Point72 Asset Management L.P. lifted its position in enGene by 1,410.3% in the third quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company's stock valued at $4,376,000 after buying an additional 619,100 shares during the last quarter. Institutional investors and hedge funds own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.